Biomarkers /
KIT
Overview
KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, also known as CD117) encodes for the mast/stem cell growth factor receptor Kit protein. It is a receptor tyrosine kinase (RTK) expressed on a wide variety of cell types. The ligand for KIT is stem cell factor (SCF). Binding of the KIT ligand SCF to the KIT RTK activates downstream signaling pathways involved in mediating pro-growth and pro-survival signals within the cell. Mutant KIT has been implicated in the pathogenesis of several cancers including melanoma, acute leukemia, and gastrointestinal stromal tumor (GIST; PMID: 14645423; PMID: 9438854
KIT is altered in 2.86% of all cancers with gastrointestinal stromal tumor, lung adenocarcinoma, colon adenocarcinoma, conventional glioblastoma multiforme, and melanoma having the greatest prevalence of alterations [3].
The most common alterations in KIT are KIT Mutation (2.41%), KIT Exon 11 Mutation (0.85%), KIT Amplification (0.67%), KIT Deletion (0.50%), and KIT Exon 11 Deletion (0.49%) [3].
Biomarker-Directed Therapies
KIT is a predictive biomarker for use of imatinib, sunitinib, sorafenib, dasatinib, and nilotinib in patients.
Thymic carcinoma, melanoma, and gastrointestinal stromal tumor have the most therapies with KIT as a predictive biomarker.
Of the therapies with KIT as a predictive biomarker, 1 is FDA-approved in at least one clinical setting and 1 has NCCN guidelines in at least one clinical setting.
KIT W557_K558del, KIT D816V, KIT V654A, KIT T670I, and KIT N822K are the top alterations on KIT targeted by therapies [4].
Dasatinib +
Thymic Carcinoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Imatinib +
Gastrointestinal Stromal Tumor -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (FDA) | |
Note: Imatinib is indicated for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). |
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) |
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN) | |
Note: Confers intermediate sensitivity; Higher doses of imatinib may be more effective. |
Melanoma -
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Resistance |
Clinical Setting(s): Metastatic (NCCN) |
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (NCCN, MCG) |
Biomarker Criteria: | Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Thymic Carcinoma -
Biomarker Criteria: | Predicted Response: Theoretical Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Resistance |
Clinical Setting(s): Metastatic (MCG) |
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Nilotinib +
Melanoma -
Sorafenib +
Melanoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Thymic Carcinoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Sunitinib +
Melanoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Thymic Carcinoma -
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Theoretical Primary Sensitivity |
Clinical Setting(s): Metastatic (MCG) |
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Theoretical Primary Resistance |
Clinical Setting(s): Metastatic (MCG) |
Clinical Trials
KIT status serves as an inclusion eligibility criteria in 85 clinical trials, of which 58 are open and 27 are closed. Of the trials that contain KIT status as an inclusion criterion, 1 is early phase 1 (0 open), 19 are phase 1 (11 open), 8 are phase 1/phase 2 (6 open), 43 are phase 2 (32 open), 3 are phase 2/phase 3 (3 open), 10 are phase 3 (6 open), and 1 is no phase specified (0 open).
Trials with KIT status in the inclusion eligibility criteria most commonly target acute myeloid leukemia, gastrointestinal stromal tumor, malignant solid tumor, melanoma, and non-small cell lung carcinoma [4].
The most frequent alteration to serve as an inclusion eligibility criterion is KIT Mutation [4].
Fludarabine, allogeneic hematopoietic stem cell transplantation, cyclophosphamide, cytarabine, and imatinib are the most frequent therapies in trials with KIT as an inclusion criteria [4].
Significance of KIT in Diseases
Gastrointestinal Stromal Tumor +
KIT is altered in 71.19% of gastrointestinal stromal tumor patients [3].
KIT is an inclusion criterion in 18 clinical trials for gastrointestinal stromal tumor, of which 16 are open and 2 are closed. Of the trials that contain KIT status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (8 open), and 6 are phase 3 (4 open) [4].
Imatinib has evidence of efficacy in patients with KIT mutation in gastrointestinal stromal tumor [4].
Melanoma +
KIT is altered in 6.55% of melanoma patients [3].
KIT is an inclusion criterion in 13 clinical trials for melanoma, of which 7 are open and 6 are closed. Of the trials that contain KIT status and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (4 open), and 1 is phase 3 (0 open) [4].
Imatinib, nilotinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in melanoma [4].
Thymic Carcinoma +
KIT is altered in 6.25% of thymic carcinoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Dasatinib, imatinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in thymic carcinoma [4].
Acute Myeloid Leukemia +
KIT is altered in 2.0% of acute myeloid leukemia patients [3].
KIT is an inclusion criterion in 36 clinical trials for acute myeloid leukemia, of which 22 are open and 14 are closed. Of the trials that contain KIT status and acute myeloid leukemia as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (8 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].
Myelodysplastic Syndromes +
KIT is altered in 0.89% of myelodysplastic syndromes patients [3].
KIT is an inclusion criterion in 22 clinical trials for myelodysplastic syndromes, of which 13 are open and 9 are closed. Of the trials that contain KIT status and myelodysplastic syndromes as inclusion criteria, 11 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (5 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Malignant Solid Tumor +
KIT is altered in 3.15% of malignant solid tumor patients [3].
KIT is an inclusion criterion in 16 clinical trials for malignant solid tumor, of which 12 are open and 4 are closed. Of the trials that contain KIT status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (7 open) [4].
Acute Lymphoblastic Leukemia +
KIT is an inclusion criterion in 14 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 6 are closed. Of the trials that contain KIT status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Chronic Myeloid Leukemia +
KIT is altered in 0.85% of chronic myeloid leukemia patients [3].
KIT is an inclusion criterion in 11 clinical trials for chronic myeloid leukemia, of which 7 are open and 4 are closed. Of the trials that contain KIT status and chronic myeloid leukemia as inclusion criteria, 5 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].
Multiple Myeloma +
KIT is altered in 0.4% of multiple myeloma patients [3].
KIT is an inclusion criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain KIT status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 4 are phase 2 (4 open), and 1 is no phase specified (0 open) [4].
Chronic Myelomonocytic Leukemia +
KIT is altered in 2.54% of chronic myelomonocytic leukemia patients [3].
KIT is an inclusion criterion in 7 clinical trials for chronic myelomonocytic leukemia, of which 5 are open and 2 are closed. Of the trials that contain KIT status and chronic myelomonocytic leukemia as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].
Non-Small Cell Lung Carcinoma +
KIT is altered in 2.09% of non-small cell lung carcinoma patients [3].
KIT is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain KIT status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 4 are phase 2 (4 open) [4].
Hodgkin Lymphoma +
KIT is an inclusion criterion in 7 clinical trials for hodgkin lymphoma, of which 3 are open and 4 are closed. Of the trials that contain KIT status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Acute Biphenotypic Leukemia +
KIT is an inclusion criterion in 6 clinical trials for acute biphenotypic leukemia, of which 2 are open and 4 are closed. Of the trials that contain KIT status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Chronic Lymphocytic Leukemia +
KIT is an inclusion criterion in 5 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain KIT status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Lymphoma +
KIT is altered in 1.15% of lymphoma patients [3].
KIT is an inclusion criterion in 4 clinical trials for lymphoma, of which 3 are open and 1 is closed. Of the trials that contain KIT status and lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].
Myeloproliferative Neoplasm +
KIT is altered in 0.59% of myeloproliferative neoplasm patients [3].
KIT is an inclusion criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and 1 is closed. Of the trials that contain KIT status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm +
KIT is altered in 2.7% of myelodysplastic/myeloproliferative neoplasm patients [3].
KIT is an inclusion criterion in 3 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 1 is closed. Of the trials that contain KIT status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].
Acute Leukemia +
KIT is altered in 1.95% of acute leukemia patients [3].
KIT is an inclusion criterion in 3 clinical trials for acute leukemia, of which 1 is open and 2 are closed. Of the trials that contain KIT status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Therapy-Related Myelodysplastic Syndrome +
KIT is altered in 1.41% of therapy-related myelodysplastic syndrome patients [3].
KIT is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain KIT status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].
Breast Carcinoma +
KIT is altered in 1.47% of breast carcinoma patients [3].
KIT is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].
Pancreatic Carcinoma +
KIT is altered in 0.62% of pancreatic carcinoma patients [3].
KIT is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +
KIT is altered in 0.51% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].
KIT is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].
Double-Hit Lymphoma +
KIT is an inclusion criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain KIT status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].
Myelodysplastic Syndrome With Excess Blasts-2 +
KIT is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 1 is closed. Of the trials that contain KIT status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (2 open) [4].
Refractory Anemia With Excess Blasts +
KIT is an inclusion criterion in 3 clinical trials for refractory anemia with excess blasts, of which 1 is open and 2 are closed. Of the trials that contain KIT status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].
Small Lymphocytic Lymphoma +
KIT is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain KIT status and small lymphocytic lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].
Systemic Mastocytosis +
KIT is altered in 35.29% of systemic mastocytosis patients [3].
KIT is an inclusion criterion in 2 clinical trials for systemic mastocytosis, of which 2 are open and 0 are closed. Of the trials that contain KIT status and systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [4].
Soft Tissue Sarcoma +
KIT is altered in 30.77% of soft tissue sarcoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Anaplastic Large Cell Lymphoma +
KIT is altered in 2.86% of anaplastic large cell lymphoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Colorectal Carcinoma +
KIT is altered in 2.04% of colorectal carcinoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Bladder Carcinoma +
KIT is altered in 1.85% of bladder carcinoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Head And Neck Squamous Cell Carcinoma +
KIT is altered in 1.89% of head and neck squamous cell carcinoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Ovarian Carcinoma +
KIT is altered in 1.69% of ovarian carcinoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
KIT is altered in 1.41% of adenocarcinoma of the gastroesophageal junction patients [3].
KIT is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain KIT status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [4].
Head And Neck Carcinoma +
KIT is altered in 2.11% of head and neck carcinoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
KIT is altered in 1.03% of B-cell non-hodgkin lymphoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].
Follicular Lymphoma +
KIT is altered in 0.92% of follicular lymphoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Mantle Cell Lymphoma +
KIT is altered in 0.56% of mantle cell lymphoma patients [3].
KIT is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Burkitt Lymphoma +
KIT is an inclusion criterion in 2 clinical trials for Burkitt lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Lymphoblastic Lymphoma +
KIT is an inclusion criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Lymphoplasmacytic Lymphoma +
KIT is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Marginal Zone Lymphoma +
KIT is an inclusion criterion in 2 clinical trials for marginal zone lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and marginal zone lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Prolymphocytic Leukemia +
KIT is an inclusion criterion in 2 clinical trials for prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KIT status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].
Secondary Acute Myeloid Leukemia +
KIT is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KIT status and secondary acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].
Systemic Mastocytosis With An Associated Hematological Neoplasm (SM-AHN) +
KIT is altered in 37.5% of systemic mastocytosis with an associated hematological neoplasm (SM-AHN) patients [3].
KIT is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains KIT status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].
Acral Lentiginous Melanoma +
KIT is altered in 11.89% of acral lentiginous melanoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (0 open) [4].
Malignant Germ Cell Tumor +
KIT is altered in 9.28% of malignant germ cell tumor patients [3].
KIT is an inclusion criterion in 1 clinical trial for malignant germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant germ cell tumor as inclusion criteria, 1 is phase 1 (1 open) [4].
Nasal Cavity And Paranasal Sinus Carcinoma +
KIT is altered in 4.35% of nasal cavity and paranasal sinus carcinoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Uterine Neoplasm +
KIT is altered in 3.43% of malignant uterine neoplasm patients [3].
KIT is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Small Cell Lung Carcinoma +
KIT is altered in 4.92% of small cell lung carcinoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Laryngeal Neoplasm +
KIT is altered in 2.35% of malignant laryngeal neoplasm patients [3].
KIT is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Salivary Gland Neoplasm +
KIT is altered in 2.04% of malignant salivary gland neoplasm patients [3].
KIT is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Oropharyngeal Squamous Cell Carcinoma +
KIT is altered in 1.84% of oropharyngeal squamous cell carcinoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
T-Cell And NK-Cell Neoplasm +
KIT is altered in 1.79% of T-cell and NK-cell neoplasm patients [3].
KIT is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Diffuse Large B-Cell Lymphoma +
KIT is altered in 1.51% of diffuse large B-cell lymphoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Lip And Oral Cavity Carcinoma +
KIT is altered in 1.72% of lip and oral cavity carcinoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Hepatobiliary Neoplasm +
KIT is altered in 1.39% of malignant hepatobiliary neoplasm patients [3].
KIT is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Esophageal Squamous Cell Carcinoma +
KIT is altered in 0.69% of esophageal squamous cell carcinoma patients [3].
KIT is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome +
KIT is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KIT status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].
Acute Promyelocytic Leukemia +
KIT is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and acute promyelocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].
Acute Undifferentiated Leukemia +
KIT is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Adult T-Cell Leukemia/Lymphoma +
KIT is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].
Aggressive Systemic Mastocytosis +
KIT is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains KIT status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].
Aplastic Anemia +
KIT is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Bronchogenic Carcinoma +
KIT is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Juvenile Myelomonocytic Leukemia +
KIT is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Mast Cell Leukemia +
KIT is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Mature B-Cell Lymphoma/Leukemia +
KIT is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Mature T-Cell And NK-Cell Lymphoma/Leukemia +
KIT is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].
Mediastinal Large B-Cell Lymphoma +
KIT is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].
Myelodysplastic Syndrome With Excess Blasts-1 +
KIT is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +
KIT is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].
Plasma Cell Leukemia +
KIT is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].
Refractory Anemia +
KIT is an inclusion criterion in 1 clinical trial for refractory anemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and refractory anemia as inclusion criteria, 1 is phase 2 (0 open) [4].
Small Lymphocytic Leukemia +
KIT is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].
Therapy-Related Acute Myeloid Leukemia +
KIT is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
Therapy-Related Chronic Myelomonocytic Leukemia +
KIT is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.